Education
About Us
Working with TipRanks
Follow Us
Myriad Genetics (MYGN)
NASDAQ:MYGN
Earnings Data
Report Date
Mar 03, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.02Last Year’s EPS
0.03Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture. While there were strong operational efficiencies and promising strategic initiatives that promise future growth, these were counterbalanced by current revenue declines and challenges in certain segments, notably prenatal testing. The company is taking proactive steps to address these challenges and remains optimistic about future prospects.Company Guidance
Strong Volume Growth in Key Segments
MyRisk in oncology saw a 16% volume growth year-over-year, and MyRisk for unaffected grew by 11%. GeneSight volume increased by 8%, showing acceleration from the first half of 2025.
High Adjusted Gross Margin
The company reported a strong adjusted gross margin of 70.1% in the third quarter, reflecting operational efficiency and strong test mix.
Strategic Partnerships and Product Launches
The company entered into a collaboration with SOPHiA GENETICS and is on track to launch the updated MyRisk test and a new Prolaris prostate cancer test in 2026. These initiatives are expected to accelerate growth.
Positive Adjusted EBITDA and Free Cash Flow
Reported an adjusted EBITDA of $10.3 million and adjusted free cash flow of $18.6 million, demonstrating the profitability and cash-generating potential of the business.
Reaffirmation of 2025 Financial Guidance
The company reaffirmed its full-year revenue guidance of $818 million to $828 million, with a gross margin range of 69.5% to 70% and adjusted EBITDA guidance of $27 million to $33 million.
MYGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MYGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 03, 2025 | $8.18 | $6.46 | -21.03% |
Aug 05, 2025 | $3.87 | $5.67 | +46.51% |
May 06, 2025 | $7.27 | $4.27 | -41.27% |
Feb 24, 2025 | $13.78 | $11.74 | -14.80% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Myriad Genetics (MYGN) report earnings?
Myriad Genetics (MYGN) is schdueled to report earning on Mar 03, 2026, TBA (Confirmed).
What is Myriad Genetics (MYGN) earnings time?
Myriad Genetics (MYGN) earnings time is at Mar 03, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MYGN EPS forecast?
MYGN EPS forecast for the fiscal quarter 2025 (Q4) is -0.02.